MA31549B1 - Procede pour predire la reponse a un traitement - Google Patents
Procede pour predire la reponse a un traitementInfo
- Publication number
- MA31549B1 MA31549B1 MA30621A MA30621A MA31549B1 MA 31549 B1 MA31549 B1 MA 31549B1 MA 30621 A MA30621 A MA 30621A MA 30621 A MA30621 A MA 30621A MA 31549 B1 MA31549 B1 MA 31549B1
- Authority
- MA
- Morocco
- Prior art keywords
- marker gene
- treatment
- patient
- growth factor
- response
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000003550 marker Substances 0.000 abstract 7
- 108090000623 proteins and genes Proteins 0.000 abstract 7
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 229940116977 epidermal growth factor Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000001131 transforming effect Effects 0.000 abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017663 | 2005-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31549B1 true MA31549B1 (fr) | 2010-08-02 |
Family
ID=35511140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30621A MA31549B1 (fr) | 2005-08-12 | 2008-02-06 | Procede pour predire la reponse a un traitement |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7700299B2 (OSRAM) |
| EP (2) | EP1915460B1 (OSRAM) |
| JP (1) | JP2009504142A (OSRAM) |
| KR (2) | KR20080034922A (OSRAM) |
| CN (2) | CN101705287A (OSRAM) |
| AR (1) | AR057323A1 (OSRAM) |
| AT (2) | ATE493514T1 (OSRAM) |
| AU (2) | AU2006281746B2 (OSRAM) |
| BR (1) | BRPI0615001A2 (OSRAM) |
| CA (1) | CA2616913A1 (OSRAM) |
| CL (1) | CL2010000720A1 (OSRAM) |
| CR (1) | CR9686A (OSRAM) |
| CY (1) | CY1111612T1 (OSRAM) |
| DE (1) | DE602006019265D1 (OSRAM) |
| DK (1) | DK1915460T3 (OSRAM) |
| EC (1) | ECSP088171A (OSRAM) |
| ES (1) | ES2356066T3 (OSRAM) |
| HR (1) | HRP20110171T1 (OSRAM) |
| IL (1) | IL188923A0 (OSRAM) |
| MA (1) | MA31549B1 (OSRAM) |
| MX (1) | MX2008001926A (OSRAM) |
| NO (1) | NO20080371L (OSRAM) |
| NZ (1) | NZ565270A (OSRAM) |
| PL (1) | PL1915460T3 (OSRAM) |
| PT (1) | PT1915460E (OSRAM) |
| RS (1) | RS51859B (OSRAM) |
| RU (2) | RU2408735C2 (OSRAM) |
| SI (1) | SI1915460T1 (OSRAM) |
| TW (1) | TW200741010A (OSRAM) |
| UA (1) | UA93989C2 (OSRAM) |
| WO (1) | WO2007019899A2 (OSRAM) |
| ZA (1) | ZA201102688B (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AU2001264696B2 (en) | 2000-05-19 | 2007-01-04 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| ZA200701234B (en) * | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| CA2596133C (en) | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| WO2007025044A2 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| CA2677108A1 (en) * | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
| JP5433189B2 (ja) * | 2007-09-28 | 2014-03-05 | 承一 尾崎 | Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法 |
| EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| EP2237792B1 (en) * | 2007-12-26 | 2017-05-24 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| KR20160066557A (ko) * | 2008-03-14 | 2016-06-10 | 제넨테크, 인크. | 약물 저항성과 관련된 유전적 변이 |
| AU2009246398A1 (en) | 2008-05-14 | 2009-11-19 | Bristol-Myers Squibb Company | Predictors of patient response to treatment with EGF receptor inhibitors |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010065568A2 (en) | 2008-12-01 | 2010-06-10 | Laboratory Corporation Of America Holdings | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 |
| SG172984A1 (en) * | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-2 expression |
| BRPI1007321A2 (pt) | 2009-01-15 | 2018-07-10 | Laboratory Corp America Holdings | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| KR20130105782A (ko) * | 2010-04-18 | 2013-09-26 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | ErbB/ErbB 리간드 관련된 질병을 치료하기 위한 분자 및 이들의 사용 방법 |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| WO2013103384A1 (en) | 2012-01-06 | 2013-07-11 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| WO2012094636A2 (en) * | 2011-01-07 | 2012-07-12 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| CA2851314A1 (en) * | 2011-10-06 | 2013-04-11 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
| PT4403228T (pt) | 2011-10-14 | 2025-10-07 | Hoffmann La Roche | Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo |
| SG10201901922VA (en) | 2012-01-06 | 2019-04-29 | Elcelyx Therapeutics Inc | Compositions and methods for treating metabolic disorders |
| US9815904B2 (en) | 2013-04-16 | 2017-11-14 | Genetech, Inc. | Pertuzumab variants and evaluation thereof |
| CA2919477A1 (en) * | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
| EP2876442A1 (en) | 2013-11-22 | 2015-05-27 | Institut de Cancérologie de l'Ouest | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer |
| KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
| EP3791891A1 (en) | 2014-07-17 | 2021-03-17 | Brian J. Czerniecki | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| PT3302551T (pt) | 2015-05-30 | 2024-08-21 | H Hoffnabb La Roche Ag | Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente |
| CA2992925A1 (en) * | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN105403704A (zh) * | 2015-12-31 | 2016-03-16 | 苏州市博纳泰科生物技术有限公司 | Her-2的荧光免疫层析检测方法及试剂盒 |
| CA3040913A1 (en) | 2016-11-04 | 2018-05-11 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| US20180221481A1 (en) | 2016-12-28 | 2018-08-09 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| LT3570884T (lt) | 2017-01-17 | 2020-12-10 | Genentech, Inc. | Poodinės her2 antikūnų kompozicijos |
| JP6992081B2 (ja) | 2017-03-02 | 2022-02-03 | ジェネンテック， インコーポレイテッド | Ｈｅｒ２陽性乳癌のアジュバント治療 |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| CN119685309A (zh) * | 2018-05-25 | 2025-03-25 | 柏业公司 | 用于预防和治疗纤维化相关疾病和呼吸系统疾病的双调蛋白基因特异性双链寡核苷酸和包含其的组合物 |
| MX2022015884A (es) | 2020-06-29 | 2023-04-03 | Genentech Inc | Combinacion de dosis fija de pertuzumab mas trastuzumab. |
| EP4568994A1 (en) * | 2022-08-09 | 2025-06-18 | Heligenics, Inc. | Method for evaluating clinical relevance of genetic variance |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US6759217B2 (en) * | 1996-03-26 | 2004-07-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| CN101412758A (zh) | 1996-10-18 | 2009-04-22 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| BRPI0012198B8 (pt) | 1999-06-25 | 2021-05-25 | Genentech Inc | anticorpos humanizados, composição e imunoconjugado |
| DK1918386T3 (da) * | 2002-03-13 | 2012-01-02 | Genomic Health Inc | Genekspressionsprofiler i biopsier af tumorvæv |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| AU2003273218C1 (en) | 2002-07-15 | 2019-01-17 | F. Hoffmann - La Roche Ag | Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies |
| JP4609930B2 (ja) * | 2002-12-11 | 2011-01-12 | ベンタナ・メディカル・システムズ・インコーポレーテッド | Ｈｅｒ−２指向性治療に対する応答を予測する方法 |
| CA2515096A1 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| EP1613732A4 (en) | 2003-04-01 | 2012-03-14 | Monogram Biosciences Inc | INTRA-CELLULAR COMPLEXES AS BIOMARKERS |
| EP2348110B1 (en) | 2003-05-30 | 2013-03-27 | OncoTherapy Science, Inc. | Process for screening a drug response in cancer patients |
| EP1653986A4 (en) | 2003-08-01 | 2007-03-14 | Smithkline Beecham Corp | TREATMENT OF CANCERS EXPRESSING P95 SP ERBB2 / SP |
| EP1682675A2 (en) | 2003-10-28 | 2006-07-26 | Bayer HealthCare AG | Methods and compositions for the response prediction of malignant neoplasia to treatment |
| TWM256978U (en) * | 2004-04-02 | 2005-02-11 | Nventec Appliances Corp | Electronic device |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| RU2300111C2 (ru) * | 2005-06-15 | 2007-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ прогнозирования течения заболевания раком молочной железы |
-
2006
- 2006-05-19 US US11/438,033 patent/US7700299B2/en not_active Expired - Fee Related
- 2006-05-23 TW TW095118273A patent/TW200741010A/zh unknown
- 2006-05-24 ES ES06743052T patent/ES2356066T3/es active Active
- 2006-05-24 CN CN200910204668A patent/CN101705287A/zh active Pending
- 2006-05-24 DK DK06743052.0T patent/DK1915460T3/da active
- 2006-05-24 KR KR1020087003440A patent/KR20080034922A/ko not_active Ceased
- 2006-05-24 UA UAA200803055A patent/UA93989C2/ru unknown
- 2006-05-24 CN CNA2006800289513A patent/CN101405405A/zh not_active Withdrawn
- 2006-05-24 AT AT06743052T patent/ATE493514T1/de active
- 2006-05-24 SI SI200630946T patent/SI1915460T1/sl unknown
- 2006-05-24 RS RS20110132A patent/RS51859B/sr unknown
- 2006-05-24 HR HR20110171T patent/HRP20110171T1/hr unknown
- 2006-05-24 EP EP06743052A patent/EP1915460B1/en active Active
- 2006-05-24 AT AT10156100T patent/ATE539171T1/de active
- 2006-05-24 MX MX2008001926A patent/MX2008001926A/es active IP Right Grant
- 2006-05-24 PT PT06743052T patent/PT1915460E/pt unknown
- 2006-05-24 NZ NZ565270A patent/NZ565270A/en not_active IP Right Cessation
- 2006-05-24 BR BRPI0615001-2A patent/BRPI0615001A2/pt not_active IP Right Cessation
- 2006-05-24 CA CA002616913A patent/CA2616913A1/en not_active Abandoned
- 2006-05-24 DE DE602006019265T patent/DE602006019265D1/de active Active
- 2006-05-24 WO PCT/EP2006/004950 patent/WO2007019899A2/en not_active Ceased
- 2006-05-24 KR KR1020117011685A patent/KR20110074921A/ko not_active Ceased
- 2006-05-24 PL PL06743052T patent/PL1915460T3/pl unknown
- 2006-05-24 AR ARP060102149A patent/AR057323A1/es not_active Application Discontinuation
- 2006-05-24 RU RU2008108907/10A patent/RU2408735C2/ru not_active IP Right Cessation
- 2006-05-24 AU AU2006281746A patent/AU2006281746B2/en not_active Ceased
- 2006-05-24 JP JP2008525399A patent/JP2009504142A/ja active Pending
- 2006-05-24 EP EP10156100A patent/EP2196547B1/en active Active
-
2008
- 2008-01-21 NO NO20080371A patent/NO20080371L/no not_active Application Discontinuation
- 2008-01-21 IL IL188923A patent/IL188923A0/en unknown
- 2008-01-24 CR CR9686A patent/CR9686A/es not_active Application Discontinuation
- 2008-02-06 MA MA30621A patent/MA31549B1/fr unknown
- 2008-02-11 EC EC2008008171A patent/ECSP088171A/es unknown
-
2009
- 2009-11-24 US US12/624,443 patent/US20100112603A1/en not_active Abandoned
-
2010
- 2010-04-19 RU RU2010115252/10A patent/RU2010115252A/ru not_active Application Discontinuation
- 2010-07-06 CL CL2010000720A patent/CL2010000720A1/es unknown
-
2011
- 2011-03-15 CY CY20111100286T patent/CY1111612T1/el unknown
- 2011-04-11 ZA ZA2011/02688A patent/ZA201102688B/en unknown
- 2011-05-19 AU AU2011202339A patent/AU2011202339A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31549B1 (fr) | Procede pour predire la reponse a un traitement | |
| Novais et al. | Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice | |
| Lorenzo-Morales et al. | Early diagnosis of amoebic keratitis due to a mixed infection with Acanthamoeba and Hartmannella | |
| ATE421589T1 (de) | Optisches abbildungssystem zur darstellung der genexpression des gesamten körpers und anwendungen | |
| Zeb et al. | Genetic diversity, piroplasms and trypanosomes in Rhipicephalus microplus and Hyalomma anatolicum collected from cattle in northern Pakistan | |
| EA200501667A1 (ru) | Рецепторный комплекс тканезащитных цитокинов, способы идентификации тканезащитных соединений и их применение | |
| WO2004011624A3 (en) | Double stranded rna structures and constructs, and methods for generating and using the same | |
| Krawczyk et al. | Quantitative microbial population study reveals geographical differences in bacterial symbionts of Ixodes ricinus | |
| EP1572964A4 (en) | STRUCTURES AND CONSTRUCTIONS OF DOUBLE STRANDED RNA AND METHODS FOR THEIR GENERATION AND USE | |
| Tajer et al. | BMP heterodimers signal via distinct type I receptor class functions | |
| SG156625A1 (en) | Method for measuring resistance or sensitivity to docetaxel | |
| WO2008104953A3 (en) | Methods and targets for identifying compounds for regulating rhinovirus infection | |
| MA40761B1 (fr) | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr | |
| BRPI0410634A (pt) | processo | |
| EP1987165A4 (en) | Gene with influence on the human memory | |
| Erdélyi et al. | Fatal acute babesiosis in captive grey wolves (Canis lupus) due to Babesia canis | |
| EP1519725A4 (en) | PROCESS FOR TARGETING QUADRUPLEX DNA | |
| Shivasabesan et al. | Disseminated Aspergillus lentulus infection in a heart transplant recipient: a case report | |
| ATE482976T1 (de) | Defensinproteine | |
| Aouadi et al. | Perceived wetland wildlife in a North African urban setting: conservation implications | |
| Njitchouang et al. | A new transmission risk index for human African trypanosomiasis and its application in the identification of sites of high transmission of sleeping sickness in the Fontem focus of southwest Cameroon | |
| Scarpetta | The G7 Primary Health Care Universal Knowledge Initiative | |
| MX2025012729A (es) | Composiciones de mivelsiran y metodos de uso de las mismas | |
| EP2267456A3 (en) | Prognostic methods for congestive heart failure | |
| Belasen | The Impacts of Habitat Fragmentation on Amphibian Genetics and Health in the Brazilian Atlantic Forest Biodiversity Hotspot |